Synapse Open Synapse
Biology

First Tracks climbs on ‘impressive’ celiac study data

BioPharma Dive · · 2 min read

Initial study findings strengthened some analysts’ belief that First Tracks’ drug, one of a few in development aimed at the protein CD122, might have “pipeline-in-a-product” potential.

Latest from BioPharma Dive